Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

EADB (Alzheimer Disease European DNA biobank), IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium), RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia), Netherlands Brain Bank (NBB), The GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, DESGESCO (Dementia Genetics Spanish Consortium)

Research output: Contribution to JournalErratum / CorrigendumAcademic

Abstract

The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.

Original languageEnglish
Pages (from-to)959-962
Number of pages4
JournalActa Neuropathologica
Volume139
Issue number5
Early online date18 Jan 2020
DOIs
Publication statusPublished - May 2020

Bibliographical note

Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8.

Funding

This work was supported in part by RiMod-FTD, an EU Joint Programme-Neurodegenerative Disease Research (JPND) project. We acknowledge the following contributors to RiMoD-FTD: John van Swieten (Erasmus University Medical Center, Rotterdam, the Netherlands); Simon Mead (UCL Institute of Prion Diseases, London, UK); Isabel LeBer (Sorbonne Universités, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, Paris, France); Matthis Synofzik (Department of Neurodegenerative Diseases, Center for Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany).

Fingerprint

Dive into the research topics of 'Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity'. Together they form a unique fingerprint.

Cite this